Menu
No results found.
300122
ZHIFEI BIOLOGICAL – SHE
Weekly Share Price & Valuation Overview
Market Overview
Open
23.1600
Close
23.4600
High
23.5000
Low
23.1500
Trend
0.16607
ZHIFEI BIOLOGICAL
China
• SHE - Shenzhen Stock Exchange
• 300122
• Currency: CNY
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine under the Mening A Con brand; and other developed products. It also provides cold storage services. Chongqing Zhifei Biological Products Co., Ltd. was founded in 2002 and is based in Chongqing, China.
Key strengths
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
Potential weaknesses
- Debt/EBITDA >4 — elevated leverage vs earnings capacity.
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 55.30B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 67.34B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 17.05B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 4.89B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY 735.99M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 7.12
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.11
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 4.33%
- Shares Outstanding
- 2.39B
- Float Shares
- 980.07M
- Implied Shares Outstanding
- 2.39B
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-10.34%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
4.32%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
28.71%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
1.50%
- ROA Return on assets: net income ÷ total assets.
-
0.43%
- ROE Return on equity: net income ÷ shareholder equity.
-
0.81%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
-79.20%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
17.83%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.03
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.50
- Total Cash Cash and equivalents.
- CNY 3.07B
- Total Debt Short + long-term interest-bearing debt.
- CNY 15.11B
- Net Debt Total debt − cash (negative = net cash).
- CNY 12.04B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 20.53
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY 163.84M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY -7.32B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
0.96%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-42.96%
- Cash Conversion (OpCF/EBITDA)
- 0.22
Sharemaestro House View
Risk: 2
Sharemaestro internal risk profile (0–3, higher is safer).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
40.9%
Insiders
Shares held by company insiders (officers, directors).
58.6%
Institutions
Shares held by institutions (funds, pensions).
10.9%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
None detected
Net Debt
Total debt − cash (negative = net cash).
CNY 12.04B
70.6% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
18
Methodology Notes
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:14
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.